TETmedical, Inc, is a Delaware C-corp founded in December 2021 by Professors Alex Travis and Roy Cohen of Cornell University and Dr. David R. Fischell, a serial med tech entrepreneur and Cornell Trustee Emeritus. TET (Tethered Enzyme Technology) is based on more then $6 million in grant funding to professors Travis and Cohen including a prestigious NIH Pioneer Award. Since its founding TETmedical has raised ~$4M in equity funding and $2M of new grant awards from NY State and NIH.

In 2022, TETmedical licensed the TET IP from Cornell University. In November 2024, TETmedical moved into our new facility at 22 Thornwood Drive near the airport in Ithaca, NY. TETmedical’s growing team is working on multiple TET applications funded by several non-dilutive state and federal grants for advanced research projects. Several of these grants have sub-awards to labs at Cornell University.

TETmedical is actively completing final clinical feasibility testing for its first product, the Neuron Specific Enolase Functional Activity Stroke Test (NSE-FAST), to be the first in-vitro diagnostic to ensure that no cases of acute stroke are missed. With 17% of acute ischemic strokes currently missed in the US, the NSE-FAST addresses an enormous unmet medical need. Testing will begin in 2025 toward FDA De Novo approval (targeted for 2027). Pilot clinical data shows that the NSE-FAST has the potential to provide a high sensitivity blood test for brain injury from stroke, with parallels in both market size and clinical importance to use of troponin as a diagnostic for heart attacks.

NIH and NY state grants are currently supporting both the NSE-FAST product as well as the development of an at-home liver function tests and ultra-rapid and sensitive detection of specific nucleic acid sequences that can be used for detection of target viral and other pathogens.